Caption Management Adds $11M in Centessa Pharmaceuticals plc ($CNTA)
Key Points
- Wall Street's consensus rating on $CNTA is Buy and an average price target of $44.17.
- $CNTA last traded around $39.72.
Caption Management acquired a new position in Centessa Pharmaceuticals plc ($CNTA), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 274,116 shares of Centessa Pharmaceuticals plc. Caption Management's holdings in Centessa Pharmaceuticals plc were worth $10.89 million as of its most recent filing.
Centessa Pharmaceuticals plc ($CNTA) Stock
Centessa Pharmaceuticals plc Earnings
Analysts Set New Price Targets
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.